Background {#Sec1}
==========

In 2016, there were an estimated 1.4 million people living with colorectal cancer (CRC) \[[@CR1]\]. Patients report physical and emotional complications associated with cancer treatment including nausea, vomiting, pain, depression, anxiety, and fatigue \[[@CR2], [@CR3]\]. As more states legalize cannabis for medical and recreational use, people increasingly use cannabis to treat medical conditions and associated symptomatology. Evidence supports the use of cannabis to treat chemotherapy-related nausea and vomiting, though its effectiveness relative to traditional pharmacologic agents is unclear \[[@CR4]\]. The role of cannabis to treat pain \[[@CR5]\], reduce cancer-related anorexia \[[@CR6]\], and improve quality of life among patients living with cancer remains inconclusive \[[@CR6], [@CR7]\]. With legalization of cannabis for medical and recreational use, the number of people using cannabis-containing products is likely to continue to increase. As with any other addictive substance, include alcohol or tobacco, it is important that clinicians inquire about their patients' use of cannabis and to provide evidence-based recommendations to prevent or reduce adverse health effects related to cannabis use. The prevalence and utility of cannabis use for cancer-related symptoms may be clarified by examining cannabis use among patients with a common cancer diagnosis. Using a standardized and comprehensive patient-centered outcome measurement set for patients with CRC, we assessed the use of cannabis on physical and emotional health measures and quality of life (QoL) outcomes among CRC survivors \[[@CR8]\]. We hypothesized that cannabis use would not be associated with better patient-reported functional measures nor better QoL measures.

Methods {#Sec2}
=======

This study was conducted within the Patient Outcomes To Advance Learning (PORTAL) network's CRC Cohort, a retrospective cohort of healthcare system members ≥18 years old and diagnosed with adenocarcinoma of the colon or rectum from January 1, 2010 through December 31, 2016 \[[@CR9]\].

The PORTAL CRC cohort included 13,089 people diagnosed with colorectal cancer from 2010 through 2016. Within the PORTAL CRC cohort, four healthcare systems in Minnesota, Colorado, California and Oregon conducted an online survey during July 2018 to October 2018 to assess patient reported QoL and behavioral factors, including cannabis use. We excluded patients with CRC who died (*n* = 4316) or left the health system prior to June 2018 (*n* = 1282), those without an available email address (*n* = 1005), and those with in situ CRC, prior cancer, or previous colectomy (*n* = 625). We further excluded people who were listed on the "do not contact list" (*n* = 61), who did not successfully receive the survey invitation (*n* = 165), and who did not complete the survey (*n* = 3829). Finally, we excluded people who did not answer survey questions regarding cannabis use (*n* = 22). Our final sample include 1784 participants. The study was approved by the Kaiser Permanente Colorado Institutional Review Board. Written consent was obtained from all participants.

Patients were invited via email to complete a survey that included the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) to assess patient-reported measures of functional and symptom-related outcomes and other survey domains \[[@CR10]\]. Survey questions were categorized into the following sections: family history of colorectal cancer; lifestyle and habits; medication use; pain and medication use; treatment, side effects and life after cancer; ostomy; demographics. Cannabis use (yes/no) was determined by participant responses to the following questions: "Have you used marijuana after you were diagnoses with colon or rectal cancer? (yes/no)", "After you were diagnosed with colon or rectal cancer, about how many times have you used marijuana? (1 or 2 times; 3 -- 10 times; 11 -- 40 times; 41-99 times; 100 or more times)", "Have you used marijuana in the last 30 days? (yes/no)", "During the last 30 days, on how many days did you use marijuana? (write in response)", "During the last 30 days, did you used marijuana for medical or health reasons, recreational reasons only, both medical and recreational reasons?" Participants were dichotomized into two groups, those who did use cannabis use following their CRC diagnosis and those who did not use cannabis following their CRC diagnosis, based upon their survey responses. Potency or route of cannabis use was not captured within the survey questions. Quantification of cannabis use was not included in data analysis. Demographic and medical data were extracted from health records.

Statistical analyses {#Sec3}
--------------------

We used logistic regression to estimate unadjusted and adjusted odds ratios (aORs) and 95% confidence intervals (CIs) to compare the odds of cannabis use after CRC diagnosis to patient demographics, health behaviors, comorbidity burden \[[@CR11]\], and tumor characteristics.

For QoL measures, we calculated functional and symptom scales ranging from 0 to 100 \[[@CR10]\]. Functional scales included: physical, social, role, emotional, and cognitive domains. For functional scales, a higher score represented a higher or healthier level of functioning. Symptom scales included: fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, and diarrhea. For symptoms scales, a higher score indicated a higher level of symptomatology or worse symptoms. We calculated a QLQ-C30 summary score where higher scores indicated better functioning and fewer symptoms \[[@CR12]\]. We used linear regression models to estimate unadjusted and adjusted mean differences and 95% confidence intervals (CI) for each score comparing people with CRC who used cannabis to people with CRC who did not use cannabis. Table [2](#Tab2){ref-type="table"} lists the covariates in the adjusted model. We conducted sensitivity analyses, stratified by time from CRC diagnosis to survey completion (≤ 2 years vs. \> 2 years).

Power calculation {#Sec4}
-----------------

Using PASS 15 Power Analysis and Sample Size Software (2017) (NCSS, LLC. Kaysville, Utah), we calculated that given our sample size and α = 0.05, our study had 80% power to detect a mean difference in overall QoL score of 3 or greater.

Results {#Sec5}
=======

We distributed 5635 surveys and 1784 (31.6%) CRC survivors, between 1.48 and 8.62 years from the time of their diagnosis, responded. Overall, 293 (16.4%) patients reported cannabis use following their CRC diagnosis; among these 293, 93 (31.7%) used cannabis ≥100 times, 67 (22.9%) used cannabis 3 to 10 times, and 163 (55.6%) used cannabis during the 30 days prior to survey completion.

Cannabis use was more common among younger survivors, tobacco smokers, and those with greater alcohol use (Table [1](#Tab1){ref-type="table"}). Cannabis use was more likely in patients diagnosed with stage 3 or 4 CRC than stage 1 or 2 CRC (adjusted odds ratio \[aOR\] 1.68, 95% CI 1.25 to 2.25). Table 1Demographic Data and Self-Reported Conditions of Colorectal Cancer (CRC) Survivors**No Cannabis Use after CRC DiagnosisCannabis Use after CRC DiagnosisUnadjusted OR (95% CI)Adjusted OR**^**a**^\
**(95% CI)N (%)N (%)Overall**1491 (83.6%)293 (16.4%)**Age (years)** 18--4991 (6.1%)41 (14.0%)Ref 50--64451 (30.2%)135 (46.1%)0.664 (0.44, 1.01)0.66 (0.42, 1.03) 65+949 (63.6%)117 (39.9%)0.27 (0.18, 0.42)0.28 (0.18, 0.44)**Race/ethnicity** Non-Hispanic White1214 (81.4%)253 (86.3%)Ref Non-Hispanic Black55 (3.7%)12 (4.1%)1.05 (0.55, 1.98)1.06 (0.53, 2.12) Asian/Pacific Islander134 (9.0%)12 (4.1%)0.43 (0.23, 0.79)0.36 (0.19, 0.67) Hispanic88 (5.9%)16 (5.5%)0.872 (0.50, 1.51)0.75 (0.42, 1.35)**Gender** Female766 (51.4%)131 (44.7%)Ref Male725 (48.6%)162 (55.3%)1.31 (1.02, 1.68)1.31 (1.00, 1.72)**Education** No college245 (16.4%)38 (13.0%)Ref Some college or College degree1246 (83.6%)255 (87.0%)1.32 (0.91, 1.91)1.16 (0.79, 1.72)**Marital Status** Not married /partnered471 (31.6%)98 (33.4%)Ref Married or partnered, living as married1020 (68.4%)195 (66.6%)0.92 (0.70, 1.20)0.75 (0.56, 1.00)**Healthcare system**^b^ A1141 (76.5%)231 (78.8%)Ref B155 (10.4%)33 (11.3%)1.05 (0.70, 1.57)1.02 (0.66, 1.57) C160 (10.7%)22 (7.5%)0.68 (0.43, 1.09)0.75 (0.46, 1.23) D35 (2.3%)7 (2.4%)0.99 (0.43, 2.25)0.78 (0.33, 1.85)**Smoking status** Never or Former1445 (96.9%)269 (91.8%)Ref Current46 (3.1%)24 (8.2%)2.80 (1.68, 4.67)2.71 (1.56, 4.70)**Alcohol use**  ≤ 4 times per month1032 (69.2%)146 (49.8%)Ref  \> 4 times per month459 (30.8%)147 (50.2%)2.26 (1.76, 2.92)2.17 (1.65, 2.85)**Charlson comorbidity score** 0462 (31.0%)110 (37.5%)Ref 1 or 2880 (59.0%)168 (57.3%)0.80 (0.62, 1.05)1.07 (0.80, 1.44) 3+149 (10.0%)15 (5.1%)0.42 (0.24, 0.75)0.741 (0.40, 1.36)**Stage** 1 or 2842 (56.5%)120 (41.0%)Ref 3 or 4453 (30.4%)124 (42.3%)1.92 (1.46, 2.53)1.68 (1.25, 2.25) Unstaged/Unknown196 (13.1%)49 (16.7%)1.75 (1.22, 2.53)1.52 (1.02, 2.26)**Anatomical Site** Colon1076 (72.2%)176 (60.1%)Ref Rectum415 (27.8%)117 (39.9%)1.72 (1.33, 2.24)1.30 (0.98, 1.73)^a^ Adjusted for all other variables in the table^b^ Specific site names are masked for confidentiality

After adjusting for demographics, comorbidities, stage and site of cancer diagnosis, and prescription opioid use, the mean summary QoL score was 6.14 points lower (95% CI − 8.07 to − 4.20) in people who used cannabis compared to people who did not use cannabis. People who used cannabis reported lower functioning roles (all statistically significant) and higher symptom scores (all statistically significant except for diarrhea) compared to people who did not use cannabis (Table [2](#Tab2){ref-type="table"}). Table 2Association of Cannabis Use on Quality of Life Summary Score and other Self-Reported Outcomes**Cannabis use (Yes) (*n*** **= 293)Cannabis use (No) (*n*** **= 1491)Unadjusted (95%CI)Adjusted**^**a**^**(95% CI)Mean ScoreQLQ-C30 Summary Score**^b^**76.2783.07−6.80 (−8.79, −4.80)− 6.14 (− 8.07, − 4.20)**Physical functioning^c^86.1385.071.05 (−1.36, 3.47)−2.75 (−5.01, −0.49)Social functioning^c^69.8581.52−11.67 (− 15.06, − 8.28)−9.84 (− 13.22, − 6.46)Role functioning^c^73.2982.01− 8.72 (−12.23, − 5.22)− 7.54 (− 11.03, − 4.04)Emotional functioning^c^71.5981.71−10.11 (− 12.70, − 7.52)−7.74 (− 10.35, − 5.12)Cognitive functioning^c^74.1283.11−8.99 (− 11.61, − 6.37)−8.60 (− 11.29, − 5.90)Fatigue^d^32.9224.738.18 (5.13, 11.24)8.26 (5.23, 11.29)Nausea & vomiting^d^9.704.854.85 (3.11, 6.59)3.29 (1.52, 5.07)Pain^d^24.7415.299.45 (6.31, 12.60)7.58 (4.52, 10.63)Dyspnea^d^17.4113.763.65 (0.69, 6.61)4.53 (1.53, 7.53)Insomnia^d^34.7026.658.05 (4.46, 11.64)7.13 (3.43, 10.82)Appetite loss^d^17.138.828.30 (5.70, 10.90)7.21 (4.55, 9.87)Constipation^d^22.4917.764.73 (1.49, 7.97)4.38 (1.04, 7.73)Diarrhea^d^24.6322.731.90 (−1.58, 5.38)0.83 (−2.77, 4.43)^a^ Adjusted for age, race/ethnicity, gender, education, marital status, health plan, smoking, alcohol use, Charlson comorbidity index \[[@CR11]\], stage, site, opioid use after diagnosis^b^ A high score for QoL summary score represents a high QoL^c^ A high score for a functional scale represents a high / healthy level of functioning^d^ A high score for a symptom scale / item represents a high level of symptomatology / problems

In a sensitivity analysis of recency of CRC diagnosis (\> 2 years; ≤ 2 years), there were no statistically significant differences in the results by recency of CRC diagnosis. However, all estimates within ≤2 years of diagnoses were more extreme than estimates within \> 2 years of diagnosis, indicating worse functioning and symptom severity for the cannabis use group (data not shown).

Discussion {#Sec6}
==========

We surveyed over 1700 CRC survivors and found cannabis use was not associated with improved QoL or cancer-related function or symptoms compared to CRC survivors without cannabis use. Previous studies report conflicting evidence regarding the use of cannabis to improve QoL among oncology patients \[[@CR6], [@CR7]\]. Our results suggest that, although use is relatively common among patients with CRC, they do not have improved QoL compared to non-users, even after adjusting for baseline factors. Our findings may have differed because we limited our sample to CRC patients, potential confounding by indication (whereby more symptomatic patients were users), and because the tool used to measure outcomes in this study was developed to assess patient-centered outcomes among CRC patients \[[@CR8]\].

Despite the observation that cannabis use was associated with lower QoL, functional status, and symptomatology, approximately 16% of patients in this study reported cannabis use, with the majority of recent users reporting medically-indicated use. As states increasingly legalize cannabis, more patients will likely use cannabis to treat cancer-related symptoms. Current evidence suggests that clinicians may lack the knowledge to properly advise patients about cannabis use, including in the context of co-use with alcohol and tobacco. In a survey of 400 oncology providers practicing across the United States, 70% reported insufficient knowledge to make clinical recommendations about cannabis use in people living with cancer \[[@CR13]\]. A survey of 494 health care providers in Washington state found that 64.4% had limited knowledge of cannabis-containing products or where to get them \[[@CR14]\]. Conversely, a survey of adult patients with a cancer diagnosis from a state with legalized cannabis found that 75% of respondents would like to have received education about cannabis use from their medical team, but only 15% received information \[[@CR15]\]. Our results demonstrated that patients who used cannabis generally reported feeling worse than patients who did not use cannabis. Whether patients who used cannabis discussed their cannabis use with their medical team is unknown.

Our study has several strengths, including a well-defined population of CRC survivors and the use of validated, CRC specific QoL measures \[[@CR10], [@CR12]\]. Our study limitations should also be acknowledged. Patients were excluded from this study if they lacked an email address, did not successfully receive the survey or did not complete the survey, it they died or departed from the CRC cohort, and if they did not want to be contacted. Thus, it is possible we introduced attrition bias, susceptibility bias, or self-selection bias into our study results because the final study population was not representative of the entire CRC cohort. Next, the cross-sectional design does not allow us to directly evaluate effectiveness or to examine cannabis use prior to CRC diagnosis. Most of the patients surveyed would have completed treatment several years prior to receiving the survey. Interestingly, results from our sensitivity analysis found lower QoL scores among people who used cannabis and completed the survey within 2 years of their CRC diagnosis. This finding suggests increased symptomatology related to recency of diagnosis, though these results were not statistically significant. Patients with more severe symptoms and reduced function may be more likely to use cannabis, resulting in confounding by indication. While states are increasingly legalizing medical and recreational cannabis, it remains a United States Drug Enforcement Administration (DEA) schedule I substance. For this reason, patients may be reluctant to report cannabis use on the survey, leading to misclassification and attenuation of our results. Finally, the effect of cannabis on cancer-related symptoms may correlate with the potency of the tetrahydrocannabinol (THC), its ratio of THC to cannabidiol (CBD) in the cannabis product, the frequency of use (daily, weekly, monthly) and route of use (edibles, smoked). In our study, there was a wide range of frequency of cannabis use and data on THC potency or ratio was not collected in the survey thus was unavailable.

Conclusion {#Sec7}
==========

Cannabis use was associated with lower QoL and functional status among CRC survivors. Despite inconclusive evidence to support cannabis use to manage cancer-related symptomatology, patients will likely continue to use cannabis. Health care providers should inquire about cannabis use among their patients with cancer. They should provide their patients with current evidence-based recommendations for cancer-related symptoms and explore their patient's goals for cannabis use. In this way, clinician may better understand how to best help their patients improve their functional status, reduce their symptom burden, and maximize their patient's quality of life.
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